These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
125 related items for PubMed ID: 12090906
1. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol. Stoschitzky K, Koshucharova G, Zweiker R, Lercher P, Maier R, Klein W, Zitta S, Gruber L, Lamprecht G, Lindner W. Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906 [Abstract] [Full Text] [Related]
2. Unpredicted lack of effect of exercise on plasma concentrations of carvedilol. Stoschitzky K, Zweiker R, Klein W, Zitta S, Gruber L, Lamprecht G, Lindner W. J Cardiovasc Pharmacol; 2002 Jan; 39(1):58-60. PubMed ID: 11743228 [Abstract] [Full Text] [Related]
3. Different effects of exercise on plasma concentrations of nebivolol, bisoprolol and carvedilol. Stoschitzky K, Stoschitzky G, Klein W, Müller F, Bühring K, Lamprecht G, Lindner W. Cardiovasc Drugs Ther; 2004 Mar; 18(2):135-8. PubMed ID: 15162075 [Abstract] [Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM. Am J Cardiol; 2006 Oct 02; 98(7A):17L-26L. PubMed ID: 17023228 [Abstract] [Full Text] [Related]
10. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H. Arch Pharm (Weinheim); 1993 Sep 02; 326(9):529-33. PubMed ID: 7902078 [Abstract] [Full Text] [Related]
12. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization. Spahn H, Henke W, Langguth P, Schloos J, Mutschler E. Arch Pharm (Weinheim); 1990 Aug 02; 323(8):465-9. PubMed ID: 1980583 [Abstract] [Full Text] [Related]
13. Stereoselective effects of (R)- and (S)-carvedilol in humans. Stoschitzky K, Koshucharova G, Lercher P, Maier R, Sakotnik A, Klein W, Liebmann PM, Lindner W. Chirality; 2001 Jul 02; 13(7):342-6. PubMed ID: 11400186 [Abstract] [Full Text] [Related]
14. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Stahl E, Baumgartner U, Henke D, Schölmerich J, Mutschler E, Spahn-Langguth H. Chirality; 1993 Jul 02; 5(1):1-7. PubMed ID: 8095396 [Abstract] [Full Text] [Related]
16. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. Eur J Clin Pharmacol; 1999 Jun 02; 55(4):269-77. PubMed ID: 10424319 [Abstract] [Full Text] [Related]
19. Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. Peccinini RG, Ximenes VF, Cesarino EJ, Lanchote VL. Biopharm Drug Dispos; 2008 Jul 02; 29(5):280-8. PubMed ID: 18551504 [Abstract] [Full Text] [Related]
20. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH, 369 Study Group. Am J Cardiol; 2006 Oct 02; 98(7A):39L-45L. PubMed ID: 17023231 [Abstract] [Full Text] [Related] Page: [Next] [New Search]